Lupin

BSE: 500257 | NSE: LUPIN | ISIN: INE326A01037 | SECTOR: Biotechnology & Drugs

₹ 889.05

8.25 (0.94%)
28 Jun 2023, 03:29 PM IST
View all metrics

Key Metrics

Influencer Count

-

Simple Moving Averages

DaysBSENSE

51,587.351,587.34
101,599.161,599.03
201,603.171,603.37
501,612.691,612.95
1001,482.711,482.91
3001,290.341,290.52

News

View all

Company Description

Lupin Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept. It diabetes brands include ONDERO and ONDERO MET.

Company Officers